Application of Rassf6 as marker of Alzheimer's disease

A technology for Alzheimer's disease markers, applied in the application field of Rassf6 as a marker for Alzheimer's disease, can solve problems such as unsatisfactory effects of treatment plans, achieve novel research methods, good repeatability, and broad application prospects Effect

Pending Publication Date: 2022-07-29
中山大学深圳 +1
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patented technology allows us study how an individual develops neurologically-related disorders such as dementia or Parkinsonism by studying different gene variants that are involved with these conditions. It provides valuable tools for developing therapies against them.

Problems solved by technology

The technical problem addressed in this patents relates to developing new treatments for prevention or cure of degeneration related diseases such as Alzheimers disease (Alzheimer).

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of Rassf6 as marker of Alzheimer's disease
  • Application of Rassf6 as marker of Alzheimer's disease
  • Application of Rassf6 as marker of Alzheimer's disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0072] The preparation of GABAergic neural precursor cells includes the following steps, wherein the reprogramming process of steps 1-6 is as follows figure 1 As shown, the differentiation process of step 7 is as follows figure 2 shown:

[0073] (1) Screen healthy young adults, sign the consent form for sample collection from the medical biobank, and collect blood from the right forearm and cubital vein of the volunteer under sterile conditions, about 10 mL, with EDTA-K2 anticoagulation.

[0074] (2) Peripheral blood and PBS were mixed at a ratio of 1:2, human lymphocyte separation medium was added, centrifuged at 750 g for 30 min, the middle cloud layer was taken, and mononuclear cells (PBMNC) were extracted.

[0075] (3) Cells are 0.5-1×10 6 Density was seeded in 6-well plates, cultured in mononuclear cell expansion medium, and the medium was changed every two days to expand to obtain PBMNCs.

[0076] (4) When the mononuclear cells were expanded to the 14th day, OCT3 / 4, ...

Embodiment 2

[0084] Model assessment of the therapeutic effect of MGE on AD.

[0085] 1. Method.

[0086] The γ-aminobutyric acid-producing neural precursor cells (MGE) were prepared according to the method of Example 1 above, and 5 × 10 6 AD double transgenic model mouse APP / PS1 mice (purchased from Changzhou Cavens Experimental Animal Center) were injected into the right hippocampus of the brain localizer, and the wild-type WT mice were used as the blank. Control group. details as follows:

[0087] 1.1 Preparation of labeled GABAergic neural precursor cells

[0088] Utilize the lentiviral vector pLV-CMV-MCS-EGFP-3FLAG-IRES-puro (source: Guangzhou Jidan Biotechnology Co., Ltd.) to transfect the cultured hiNPC, make it with green fluorescent label, and refer to the above Example 1 Methods, GFP-labeled hiNPCs were differentiated toward MGE to obtain γ-aminobutyric acid-ergic neural precursor cells with green fluorescent labels.

[0089] 1.2 Surgery

[0090] APP / PS1 double-transgenic m...

Embodiment 3

[0122] Validation of Rassf6 factor as a disease target in AD pathogenesis.

[0123] 1. Method.

[0124] 1.1 Serum content of clinical samples

[0125] With the consent of the Ethics Committee of the People's Hospital of Guangxi Zhuang Autonomous Region, blood samples from AD patients and normal people were collected, among which AD samples were divided into CLU site mutation group and non-CLU site mutation group. Serum was collected to determine Rassf6 content by Elisa method.

[0126] 1.2 Cell culture supernatant content

[0127] PBMNCs from AD patients and normal people with CLU site mutation were taken and reprogrammed into hiNPCs according to the method of Example 1. The content of Rassf6 in the supernatant of AD-hiNPC cells and Cont-hiNPC cells (normal human origin) was compared.

[0128] 2. Results.

[0129] The content of Rassf6 factor in clinical serum samples is as follows: Figure 40 As shown, among them, Cont, normal group; Non-CLUmutation AD, AD patient group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to application of Rassf6 as an Alzheimer's disease marker, and belongs to the technical field of disease target research. The invention discloses application of Rassf6 as a disease marker in preparation of a reagent and/or a medicine for diagnosing and/or treating Alzheimer's disease. For example, the Rassf6 can be detected to serve as a basis for AD auxiliary diagnosis, and a Rassf6-Hippo signal channel can be inhibited by acting on a Rassf6 target spot through a medicine, so that the behavioral and pathological characteristics of AD are improved, and the effect of treating AD is achieved. Important clinical significance is provided for exploring a potential target spot for treating AD, and wide application prospects are achieved.

Description

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Owner 中山大学深圳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap